Novasep expands again at biologics site in Belgium

woman with back to camera working in a laboratory
Novasep is adding a fiill finish facility at its Belgium site to handle monoclonal antibodies, as well as other low-volume products. (Michal Jarmoluk)

French CDMO Novasep says with so many of its customers developing orphan and targeted biopharmaceutical drugs, it needs to expand its fill-finish capacity. That has led it to start on a facility at its site in Seneffe, Belgium to handle low-volume biologics like viral vectors and mAbs. 

The Lyon, France-based Novasep recently said it will invest €10 million ($11.9 million) to construct the facility. It will be able to fill 20,000 to 30,000 vials per week. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“The trend towards targeted therapies has created a growing need for specialized capacities,” Jean Bléhaut, Novasep’s president of manufacturing, said in a statement. “In response, Novasep has launched a series of major projects to boost its biomanufacturing services for selected types of drug substances and fill and finish activities.”

The fill-finish facility is the third expansion project Novasep has announced in recent months as it moves toward doubling its manufacturing capacity by 2022. It is also building a €27 million commercial scale viral vector production facility at Seneffe that is slated to be qualified by the first quarter of 2019.

A €17 million clinical scale mAb production facility in Pompey, France, is slated to commissioned in the second half of 2019.

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.